Photo Credit: Eli Lilly Canada

Baqsimi® (Nasal Glucagon), Rescue Treatment for Severe Hypoglycemia Now Covered by all Federal Benefit Programs


Monday, 17 January 2022 08:33.PM

Lilly Canada is pleased to announce that as of January 1st, 2022, Baqsimi (glucagon nasal powder) is now covered by all Federal health benefit programs, which includes the Non-Insured Health Benefits (NIHB) Program, Veterans Affairs Canada (VAC), and Correctional Services of Canada (CSC).

Baqsimi is indicated for the treatment of severe hypoglycemic reactions in people with insulin-treated diabetes mellitus 4 years old and above, when impaired consciousness precludes oral carbohydrates.

"Diabetes affects one in three Canadians, and we know that many factors contribute to the successful management of the disease, including access to new treatments, supplies, and technology," says Rhonda Pacheco, General Manager, Lilly Canada. "We're so thrilled that at-need Canadians who can benefit from this important rescue treatment are able to access it, providing patients and their caregivers with protection, if they experience a severe blood sugar low."

"Expanding Baqsimi's access to Canadian patients who are at risk from complications of diabetes is so critical," says Dr. Stuart Ross, Endocrinologist, Clinical Professor of Medicines at the University of Calgary. "The threat of a severe hypoglycemic event is present every day for someone with diabetes, and for those patient populations that don't have access to emergency services and immediate assistance, such as remote First Nation's communities, this rescue treatment dramatically improves safety and care."

With the Federal benefit programs now covering Baqsimi for eligible patients, Lilly is excited to be working with the provinces to make Baqsimi available in those jurisdictions.

SOURCE: Eli Lilly Canada Inc.